Neoleukin therapeutics, inc. (AQXP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-8,642

-8,101

-59,132

-1

-2,208

-4,887

-14,993

2,918

-14,623

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-8,316

-

-8,146

-10,901

-6,711

-5,663

-5,035

-4,750

-6,412

-8,090

-6,284

-5,424

-4,228

Non-cash items:
Change in fair value of derivative liability (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

0

8

23

50

18

-76

13

-7

-9

29

14

914

Stock-based compensation (Note 5(d))

683

666

5,151

788

1,078

837

1,036

1,513

1,312

971

1,183

1,054

631

561

490

482

433

361

424

455

266

269

232

214

138

Stock-based purchase of patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

186

-

Unrealized foreign exchange loss and others

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-74

-17

-31

-75

-80

43

-468

-

-

-

-

Depreciation and amortization

171

-

-

-

41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71

-

Amortization of operating lease right-of-use assets

528

-

-

-

21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign exchange (gain) loss

14

13

-121

-143

-12

176

-306

-190

-132

132

-210

-125

-146

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

320

Fees and penalty on bank loan repayment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

100

Amortization and extinguishment of remaining discount on preferred stock upon conversion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,884

Foreign exchange loss and others

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-93

0

-125

Changes in operating assets and liabilities:
Receivable, prepayments and deposits

-266

-743

207

-157

403

-321

-894

-605

779

461

-40

58

426

-248

-414

306

465

-222

-127

47

398

-

-

-

-

Accounts and other amounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

-33

39

Prepayments and deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-143

-185

454

Accounts payable and other liabilities

568

1,729

-181

-2,495

-1,297

-6,159

-2,637

3,955

-1,631

3,925

-1,130

2,342

-3,315

1,375

-265

2,815

890

1,065

-283

-1,001

-231

-

-

-

-

Net cash used in operating activities

-6,440

-4,636

-6,532

-1,470

-2,756

-9,775

-15,394

9,181

-15,589

-11,605

-11,530

-10,303

-11,280

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,776

1,941

-735

Cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,441

-7,916

-5,872

-3,958

-4,611

-5,399

-6,300

-6,694

-4,182

-2,806

-3,803

Investing activities
Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

50,106

21,779

21,555

13,002

-

-

-

-

-

-

34,474

-

Proceeds from maturity of investments

-

-

-

-

-

0

3,000

23,000

30,000

-

-

-

-

5,499

22,023

16,550

15,025

-4,967

6,069

6,028

6,066

-

-

2,714

-

Purchase of property and equipment

107

-

-

-

-

0

-20

29

40

16

26

344

108

97

296

293

27

10

10

0

6

28

17

64

4

Net cash used in investing activities

-107

-

-

-

-

0

3,020

22,971

29,960

16,484

31,479

16,156

-108

-

-

-

-

-

-

-

-

-

-

-

-

Cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-52

-5,298

1,996

-65,680

6,059

6,028

6,060

6,051

2,205

-31,825

-4

Financing activities
Public offering of common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

53,130

Public offering costs (Note 8(e))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

50

390

4,811

Bank loan repayment, fees and penalty

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,600

Proceeds from exercise of stock options

3,392

-

-

-

-

0

0

399

203

-

-

-

-

-

-

-

-

-1

1,025

24

72

-

-

-

-

Payment on finance lease obligations

2

2

3

2

2

2

22

4

4

4

4

3

4

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

3,390

82,204

37

-2

-2

-2

-22

395

199

54

-1

374

-4

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-11

1

7

3

-1

-26

-3

-27

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash during the period

-3,168

76,787

-6,394

-1,469

-2,759

-9,803

-12,399

32,520

14,578

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

390

-

Cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-148

93,076

-52

72

0

-49

-390

45,719

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

7

-

-24

-10

41

-61

-67

56

-455

-

-

-

-

Net change in cash and cash equivalents during the period

-

-

-

-

-

-

-

-

-

-

-

-

-11,385

-

63,755

-13,221

-3,835

-69,847

94,457

633

-623

-963

-2,026

-35,022

41,912

Supplemental disclosure of cash flow information:
Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

32

Interest received

435

265

399

437

443

474

474

440

296

346

373

294

329

214

232

128

121

289

9

12

15

11

30

46

3

Non-cash investing and financing activities:
Accrued purchase of property & equipment

-

-

-

-

-

-

-

-

-

0

0

-53

-24

-

-

-

-

-

-

-

-

-

-

-

-

Accrued offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-390

50

390